The FDA in December 2022 has approved Mosunetuzumab in relapsed or refractory Follicular Lymphoma. The drug is approved for patients who had received at least two prior lines of systemic therapy.
In a multi-center study the drug showed the overall response rate (ORR) of 80% (95% CI: 70, 88), with 60% achieving complete responses. This opens up a new option for this type of lymphoma patients.
The drug is administered for 8 cycles, and after this if patients had a complete response, they can discontinue therapy. However, if patients had a partial response or stable disease on the follow up imaging scan, they continued the treatment for up to 17 cycles or unless they had a progressive disease or experienced an unacceptable toxicity.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma
The drug Mosunetuzumab-axgb is a CD20/CD3 T-cell–engaging bispecific antibody. The antibody binds to cancer cell at one site (CD20) and it’s other site engages with the T-cell (CD3) of immune system. The antibody allows the T-cell to kill the cancer cell by engaging the target cancer cell.
